IP Library › Patent Application 11810887
Patent Application
App. No. 11/810,887

High-density lipoprotein-cholesterol level elevating agent

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/810,887
Abstract

A novel high-density lipoprotein(HDL)-cholesterol level elevating agent containing a compound which has a squalene synthase inhibitory activity.

Claims (10)

1 - 43 . (canceled)

44 . A method for elevating high density lipoprotein-cholesterol in a mammal, comprising administering a compound having squalene synthase inhibitory activity, wherein said compound is N-[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidine-4-acetic acid or a salt thereof, to said mammal in an effective amount.

45 - 46 . (canceled)

47 . A method for treating familial hypercholesterolemia in a mammal, comprising administering a compound having squalene synthase inhibitory activity, wherein said compound is N-[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidine-4-acetic acid or a salt thereof, to said mammal in an effective amount.

48 - 52 . (canceled)

53 . A method for treating a mammal having hyperlipidemia, comprising administering a compound having squalene synthase inhibitory activity, wherein said compound is N-[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidine-4-acetic acid or a salt thereof, to said mammal in an effective amount.

54 . A method for treating a mammal having a disease or disorder selected from the group consisting of primary hypoalphalipoproteinemia, Tangier disease and familial hypercholesterolemia, comprising:

administering a compound having squalene synthase inhibitory activity, wherein said compound is N-[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidine-4-acetic acid or a salt thereof, to said mammal in an effective amount.

55 . A method for treating primary hypoalphalipoproteinemia in a mammal, comprising administering a compound having squalene synthase inhibitory activity, wherein said compound is N-[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidine-4-acetic acid or a salt thereof, to said mammal in an effective amount.

56 . A method for treating Tangier disease in a mammal, comprising administering a compound having squalene synthase inhibitory activity, wherein said compound is N-[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidine-4-acetic acid or a salt thereof, to said mammal in an effective amount.